Verve: Verve Therapeutics Reports Positive Initial Data From VERVE-102 Clinical Trial; Stock Climbs

Shares of Verve Therapeutics, Inc. (VERV) were gaining around 30 percent in the pre-market activity on the Nasdaq, after the clinical-stage company focused on genetic medicines for cardiovascular disease announced Monday positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102.